TUCSON, Ariz.--(BUSINESS WIRE)--The Critical Path Institute (C-Path) announced that the U.S. Food and Drug Administration (FDA) has issued three Letters of Support to C-Path’s Coalition Against Major Diseases (CAMD) consortium for the use of certain biomarkers as tools to help select clinical trial participants in the earliest stages of Parkinson’s (PD) and Alzheimer’s diseases (AD).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
